This site is intended for healthcare professionals only
Share this article

EMPEROR-Preserved: Empagliflozin first therapeutic agent to demonstrate benefits in people with HFpEF

Composite of cardiovascular death or hospitalisation for heart failure significantly reduced by 21% with empagliflozin compared to placebo.

The EMPEROR-Preserved trial explored the effect of the SGLT2 inhibitor empagliflozin in people living with heart failure with preserved ejection fraction (HFpEF), a condition which to date has had no compelling evidence-based interventions to reduce morbidity and mortality. After a median follow-up of 26 months, the primary endpoint (a composite of cardiovascular death or hospitalisation for HF) was significantly reduced by 21% with empagliflozin compared to placebo (absolute risk reduction, 3.3%; number needed to treat, 30). This was mainly driven by a significant reduction in hospitalisation for HF, as there were no statistically significant reductions in cardiovascular or all-cause death. Empagliflozin is the first therapeutic agent to robustly demonstrate statistically and clinically significant benefits in people living with HFpEF. These results should change clinical practice promptly given that SGLT2 inhibitors are already in widespread clinical use.

Click here to read Kevin Fernando’s discussion of the results in Diabetes Distilled.

Related content
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals


By clicking ‘Subscribe’, you are agreeing that are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.